WallStSmart

AngloGold Ashanti plc (AU)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 473% more annual revenue ($56.67B vs $9.89B). AU leads profitability with a 26.7% profit margin vs 24.7%. AU appears more attractively valued with a PEG of 0.78. AU earns a higher WallStSmart Score of 84/100 (A-).

AU

Exceptional Buy

84

out of 100

Grade: A-

Growth: 10.0Profit: 10.0Value: 10.0Quality: 8.5
Piotroski: 6/9Altman Z: 2.99

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 4.7Quality: 6.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AUUndervalued (+53.8%)

Margin of Safety

+53.8%

Fair Value

$242.89

Current Price

$89.55

$153.34 discount

UndervaluedFair: $242.89Overvalued
NVSSignificantly Overvalued (-243.7%)

Margin of Safety

-243.7%

Fair Value

$48.62

Current Price

$150.75

$102.13 premium

UndervaluedFair: $48.62Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AU6 strengths · Avg: 9.5/10
Return on EquityProfitability
34.4%10/10

Every $100 of equity generates 34 in profit

Operating MarginProfitability
47.2%10/10

Strong operational efficiency at 47.2%

Revenue GrowthGrowth
75.3%10/10

Revenue surging 75.3% year-over-year

EPS GrowthGrowth
63.1%10/10

Earnings expanding 63.1% YoY

Profit MarginProfitability
26.7%9/10

Keeps 27 of every $100 in revenue as profit

PEG RatioValuation
0.788/10

Growing faster than its price suggests

NVS5 strengths · Avg: 9.0/10
Market CapQuality
$286.27B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.8%10/10

Every $100 of equity generates 31 in profit

Profit MarginProfitability
24.7%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability
27.8%8/10

Strong operational efficiency at 27.8%

Free Cash FlowQuality
$1.64B8/10

Generating 1.6B in free cash flow

Areas to Watch

AU0 concerns · Avg: 0/10

No major concerns identified

NVS4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
2.2%4/10

2.2% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

PEG RatioValuation
2.542/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.6%2/10

Earnings declined 11.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : AU

The strongest argument for AU centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 26.7% and operating margin at 47.2%. Revenue growth of 75.3% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.

Bear Case : AU

No major red flags identified for AU, but monitor valuation.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.

Key Dynamics to Monitor

AU profiles as a growth stock while NVS is a value play — different risk/reward profiles.

AU carries more volatility with a beta of 0.55 — expect wider price swings.

AU is growing revenue faster at 75.3% — sustainability is the question.

NVS generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

AU scores higher overall (84/100 vs 51/100), backed by strong 26.7% margins and 75.3% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AngloGold Ashanti plc

BASIC MATERIALS · GOLD · USA

AngloGold Ashanti Limited is a gold mining company. The company is headquartered in Johannesburg, South Africa.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?